Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Chemother Pharmacol. 2009 Sep;64(4):777-83. doi: 10.1007/s00280-009-0927-7. Epub 2009 Jan 24.

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.

Author information

1
University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. rramanathan@tgen.org

Abstract

PURPOSE:

To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC).

METHODS:

Lapatinib was dosed at 1,500 mg/day orally continuously.

RESULTS:

Fifty-seven patients were accrued (BTC 17, HCC 40). Therapy was well tolerated. The response in BTC was 0% and in HCC was 5%. The progression free survival (PFS) for BTC and HCC patients was 1.8 (95% CI: 1.7-5.2) months and 2.3 (95% CI: 1.7-5.6) months. The median survival for BTC and HCC patients was 5.2 (95% CI 3.3-infinity) months and 6.2 (95% CI: 5.1-infinity) months. EGFR genotyping indicated HCC patients with <20 repeats have the lowest PFS. The occurrence of any skin rash significantly prolonged PFS and survival.

CONCLUSIONS:

Lapatinib was well-tolerated. There was evidence of activity in HCC, but therapy with lapatinib did not meet the predefined efficacy rate.

PMID:
19169683
DOI:
10.1007/s00280-009-0927-7
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center